2024 Biotech Industry Insights: IPO Trends, CRISPR Commercialization Strategies, FDA Drug Approval Process & Synthetic Biology Graduate Programs
2024 marks biotech’s strongest resurgence since 2021, with Stifel projecting 25–40 IPOs and the FDA approving 55 new drugs—66% from